Supriya Lifescience Limited (SUPRIYA) Earnings Call Transcripts

Supriya Lifescience Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Supriya Lifescience Limited reported a strong performance with revenue of INR 277 crores, reflecting a 50% year-on-year increase. For the full fiscal year, revenue reached INR 828 crores, up 19% YoY, aligning with management's guidance of approximately 20% growth. EBITDA margins improved to 35.5%, surpassing the guided range of 33% to 35%. Management reiterated their commitment to achieving INR 1,000 crores in revenue by FY '27, supported by a robust product pipeline and strategic market expansion.

Reported metrics

Guidance from management

Management reiterated their guidance for FY '27, targeting approximately 20% revenue growth and EBITDA margins of 33% to 35%. They remain confident in reaching the INR 1,000 crore revenue milestone.

What management said

So these are mainly smaller therapeutic categories like anti-allergic where we had some products, but as a strategy, we are not aggressively entering into nonregulated market because we are a very margin-focused company. So our goal is always to tap more regulated markets. So their contribution will always remain to the lower end, but yes, anti-allergic are there, like I mentioned, antihypertensive is there, which is...

See, I would like to add something on it. Ma'am, you should see first the portfolio of all the products. We are focused on China. So whatever products are not getting from India, those products are focused on the therapeutic category. So whatever products we add, we are having a future growth for the next 3 years, which we will visualize and we put. This is some information for your additional note.

What analysts pressed on

Analysts expressed concerns regarding the sustainability of the Q4 revenue run rate due to potential capacity constraints and the impact of scheduled maintenance shutdowns. There were also inquiries about pricing pressures in the European and U.S. markets.

Main topics on the call

• Regulatory Milestone — Supriya Lifescience received a favorable USFDA establishment inspection report with only one minor observation, which management noted as a testament to their compliance culture. Dr. Satish Wagh stated, "This achievement...
• Revenue Growth — The company achieved record quarterly revenues of INR 277 crores in Q4 FY '26, driven by a favorable product mix and strong demand in export markets. Management indicated that the export segment contributed 82% of total ...
• EBITDA Margin Performance — The EBITDA margin for FY '26 stood at 35.5%, exceeding the company's guidance. CFO Krishna Raghunathan mentioned, "EBITDA margins were at 35.5% for FY '26, surpassing our guided range of 33% to 35%."
• Product Launches and Pipeline — Management highlighted the successful launch of key products, including a cardiovascular product and an ADHD product, which are expected to drive future growth. They plan to launch 3 to 4 new products annually to enhance...

Read the full Supriya Lifescience Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 Supriya Lifescience Limited earnings call transcripts on record, spanning May 23, 2022 to May 28, 2026. Based on this history, Supriya Lifescience Limited reports quarterly. The most recent call on file is dated May 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SUPRIYA

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

14

First call

May 23, 2022

Most recent

May 28, 2026

Reporting cadence

quarterly